 |
|
|
|
|
|
|
A New Contract, License or Agreement are credible "News Hooks," appropriate for release to the news media. Read more:
|
|
|
InViragen Announces Exclusive Patent License Agreement with the Centers for Disease Control
Fort Collins, Colo., Sept. 14, 2006 -- InViragen, LLC, a biotechnology company dedicated to developing vaccines for emerging infectious diseases worldwide, has entered into an Exclusive Patent License Agreement with the Centers for Disease Control and Prevention (CDC). The announcement is made by Dr. Dan Stinchcomb, InViragen’s Chief Executive Officer, whose company was the recipient of the Colorado Bioscience Association (CBSA)/ Colorado Office of Economic Development and International Trade’s Venture Showcase award last year. The licensed technology is applicable to vaccines against multiple viral diseases, including dengue fever and West Nile disease. Dengue fever threatens 2.5 billion people worldwide as well as travelers to tropical countries. West Nile virus has caused thousands of debilitating fevers since its introduction in North America.
“The scientists at the Division of Vector-Borne Infectious Diseases (DVBID) of the CDC used innovative molecular biology to create novel vaccines to protect against dengue fever and West Nile disease,” said Dr. Jorge Osorio, InViragen’s Chief Scientific Officer. “They have shown that these vaccines are safe and effective in key animal models. InViragen is working with the scientists at DVBID and international collaborators to move these needed vaccines through human clinical trials and regulatory approval.” Dengue fever is a major health problem in Southeast Asia, the Pacific Islands, the Caribbean, Mexico, Central and South America and parts of Africa. The disease is a serious risk for travelers to those regions as well. Dengue fever is caused by infection with one of four different RNA viruses: DEN-1, DEN-2, DEN-3 or DEN-4. To be safe and effective, dengue vaccines must be capable of neutralizing all four of the dengue viruses. The technology developed by DVBID is based on a virus backbone that was shown to be safe and to generate long-lasting immune responses in Phase 1 clinical trials. Using this technology, InViragen is developing a four-way vaccine to protect against all four of the different viruses that cause dengue fever.
West Nile disease is a significant public health concern. The disease is caused by a single mosquito-borne RNA virus, West Nile virus. Since its emergence in New York in 1999, West Nile virus has caused over 16,000 documented human cases of disease and over 600 deaths in the United States. Using the same vaccine technology developed for the dengue vaccine, scientists at DVBID engineered a novel West Nile vaccine and demonstrated that the vaccine is safe and protects mice from West Nile virus. “Obtaining this exclusive license from the CDC is an important milestone for InViragen,” said Dr. Stinchcomb. “The license will permit InViragen to convert the exciting research findings of the DVBID into products that will improve public health worldwide.”
About InViragen InViragen, co-founded by Dr. Jorge Osorio and Dr. Dan Stinchcomb, is developing life-saving vaccines to protect against emerging infectious diseases worldwide. Over 15 million people die each year of infectious diseases. Vaccines to prevent these diseases are the most cost effective solutions to improving global health. InViragen’s lead vaccine is intended to protect against dengue fever. Dengue is a disease that potentially affects 2.5 billion people in tropical regions throughout the world as well as millions of travelers to those countries. Additionally, InViragen is developing a vaccine to protect against West Nile disease. West Nile has spread throughout the United States and North America since its introduction in the Western Hemisphere in 1999. InViragen is also designing a vaccine to protect against plague and smallpox, both of which are dangerous bioterrorist threats. InViragen has offices in Fort Collins, Colorado and Madison, Wisconsin. About the Division of Vector-Borne Infectious Diseases Established in the 1950s, the DVBID of the CDC serves as a national and international reference center for viral and bacterial diseases transmitted to humans by a “vector” such as mosquito, tick, or flea. As one of the few remaining centers responsible for these agents, the division maintains leadership and scientific competence in all major disciplines relating to the field of vector-borne infectious diseases. The mission of the DVBID is to conduct and support laboratory and epidemiologic investigations to improve diagnosis, surveillance, prevention, and control of diseases of major public health importance such as Lyme disease, dengue/dengue hemorrhagic fever, West Nile disease, yellow fever, arboviral encephalitis, plague, and tularemia. In addition, expertise is maintained for other vector-borne infectious diseases that occur only sporadically or in periodic epidemics. More information is found at http://www.cdc.gov/ncidod/dvbid
About the Colorado BioScience Association
CBSA is a not-for-profit corporation providing services and support for Colorado's growing biosciences industry. With more than 300 members, CBSA actively works to promote the growth of the industry by working for a better business environment, growing the state's biotech workforce, fighting for policies that support a strong bioscience industry in the state and speaking with a single voice on behalf of the industry. For more information, visit http://www.cobioscience.com Contact: Dr. Dan Stinchcomb, InViragen CEO, (970) 372-4754, inviragen@frii.com Here's another example of a New Contract news release:
|
Premier Awards Group Purchasing Agreement for Baxa Corporation Compounders
Englewood, CO (18 September 2003) - Premier Inc. has awarded Baxa Corporation, a market-leading manufacturer of automated solution compounders for hospital pharmacies, a five-year group purchasing agreement to sell its state-of-the-art technology to member hospitals.
The agreement, effective February 1, 2004, provides Premier members access to preferred pricing on Baxa Corporation's complete line of Exacta-Mix( and MicroMacro( Compounders. Premier, the second-largest GPO in terms of US market share, represents 1,500 hospital members, and 12.5% of the healthcare market's supply and equipment purchasing. Based on Premier's membership, Baxa anticipates that the agreement will provide enhanced access to 24% of the $100 million market for parenteral nutrition compounding.
Prior to signing this agreement, Premier had recommended the Baxa Exacta-Mix 2400 Compounder (EM2400) as part of its Technology Breakthroughs Program after a clinical review of the product's advantages for patient safety and med error reduction. Based on evidence that the EM2400's technological advances enhanced pharmacy operations and minimized the potential for compounding errors, Premier granted the EM2400 its Technology Breakthroughs Award in February 2002. Their decision was based on evidence that the EM2400.
The new agreement provides Premier members improved access to the remaining compounder products in the Baxa line: the Exacta-Mix 600 Universal Compounder for base ingredient mixing; and the MicroMacro 12 and 23 Compounders for 12 - and 23 - source compounding, respectively. MicroMacro and EM2400 Compounders provide accurate delivery for both macro and micro ingredients in a single unit. Baxa offers an extensive list of interfaces with Pharmacy IS Systems to complement its compounding hardware as well as the Abacus(tm) Windows(r)-based TPN order entry software.
For more information about Baxa and its compounders and software, visit www.baxa.com.
About Baxa Corporation
As a leading provider of devices and systems for the preparation, handling, packaging, and administration of liquid medications, Baxa manufactures and markets a wide range of healthcare products for use in hospitals, critical care units and alternate-site pharmacies. Headquartered in Englewood, Colorado, Baxa has subsidiaries and sales offices in Canada, the United Kingdom; Denmark, and Germany; and distribution partners worldwide. Further information is available at www.baxa.com.
About Premier
Premier, Inc., is a strategic alliance in US healthcare, entirely owned by more than 200 of the nation's leading hospital and healthcare systems. These systems operate or are affiliated with nearly 1,500 hospital facilities and hundreds of other healthcare sites. Premier provides an array of resources supporting health services delivery including group purchasing for more than $17 billion annually in supplies and equipment. Other resources offered by Premier are supply chain and clinical performance improvement services and insurance programs. Headquartered in San Diego, CA, Premier has other major facilities in Chicago, IL; Charlotte, NC; and Washington, DC.
###
Contact:
Marian Robinson, Vice President, Marketing
Baxa Corporation: 800.567.2292 ext. 2157 or 303.617.2157
Email: marian.robinson@baxa.com
Maggie Chamberlin Holben, APR
Absolutely Public Relations: 303.984.9801 or 303.669.3558
Email: maggie@absolutelypr.com
Here's another example of a New Contract news release:
|
October 15, 2002
FOR IMMEDIATE RELEASE
Absolutely Public Relations Announces New Client Relationship with Adventures in Color Technology, Ltd., and Establishes Denver PR Newsroom To Help Clients Gain Greater Exposure of News Announcements, Photos and Background Information
(Lakewood, Colo.) - Absolutely Public Relations, owned by Denver public relations person Maggie Chamberlin Holben, APR, now represents Adventures in Color Technology, Ltd., the Golden-based company that started in 1988 and has pioneered and continues to perfect a colored design process on soft contact lenses that helps correct serious vision problems and eye disfigurement from accidents or birth defects. Concurrently, Holben announces the rollout of Denver PR Newsroom, accessible at www.denverprnewsroom.com, to help get accurate news announcements and company information in reporters' hands as rapidly as possible during a media relations campaign.
"All Absolutely PR clients who purchase a media awareness plan - either local, trade press or national - have their news release and support information posted on Denver PR Newsroom as part of the package agreement. The newsroom takes a client announcement and quickly makes it Internet accessible during the pitching process," Holben explains, "Appropriately, Adventures in Color Technology information is available at Denver PR Newsroom (www.denverprnewsroom.com, click the Prosthetic Contacts tab)."
According to Holben, a news release can be posted for reporter access in a very short time period. Photos (.jpg or .gif), relevant information links, link to the client's website and e-mail links are all available on the page. "I focus on speed of message dissemination, accuracy and creativity at Absolutely Public Relations. Denver PR Newsroom is a key piece in this pitching process," Holben says.
Adventures in Color Technology, Ltd., provides eye-care practitioners worldwide with custom contact lenses - both hand-painted and tinted applications - for prosthetic and therapeutic use. In business for nearly 15 years, the company's practitioner clients (ophthalmologists and optometrists both in private practice and at hospital and teaching universities) now number more than 10,000. The company's website is: www.techcolors.com.
A 17-year-old Loveland, Colo., resident and accident victim suffered from double vision and a disfigured eye after emerging from a five-week coma. She subsequently was fitted with a lens from Adventures in Color Technology. According to the accident survivor, the restoration of her normal vision and appearance brought tears to her eyes. "Being able to see normally, without wearing an eye patch, was the best feeling in the world," the patient says.
"Similarly, a fourteen-year-old Castle Pines, Colo., youth born with no iris color in both eyes and experiencing extreme light sensitivity, wished for blue eyes like his parents have. He now has handsome blue eyes and is not sensitive to light as a result of lenses from Adventures in Color Technology. Our company hand painted a pair of blue irises on his soft contact lenses. They are so natural looking that few people realize these are not his own eye color," explains Stan Harper, CEO of adventures in Color Technology.
Absolutely Public Relations has been in business since 1999 and has worked with: savemountcarbon.com; Crestone Research Group; The Colorado Center of Traditional Medicine; Foster Wheeler Environmental Corporation and Arcadis, Inc., through Lakewood's Consensus Communications; McKinley Marketing Partners, InfoNow Corporation, ICG Communications, Grubb & Ellis/Martens Commercial Group, LLC; Early Music Colorado; the Joint Initiatives Sign Blind System; and Holben Building Corporation. Absolutely PR recently announced its online press kit product, accessible at www.online-presskit.com.
For more information, go to www.absolutelypr.com or www.denverprnewsroom.com. Or, call Maggie Holben at 303-984-9801.
# # # The 2002-2004 national media relations campaign for Adventures In Color Technology resulted in placements in the following media outlets: Fredericksburg (VA) Free Lance-Star, Oshkosh (WI) Northwestern, Denver Business Journal, The Courier-Journal (KY/IN), Golden (CO) Transcript, The News-Herald (Southgate, MI), Chicago Tribune, Staten Island Advance (NY), Burlington County Times (NJ), Cleveland (TN) Daily Banner, Press Enterprise (Riverside, CA), WB2 TV News Denver, KUSA TV 9News (Where in the town is Gregg Moss?), and E! Style Network segment.
Circulation reach: 1,739,748
Ad Value Equivalent: $10,710.73
Estimated National Television Viewing Audience: 33 million
In 2003-04, another Absolutely PR national media awareness campaign for a pain management client resulted in placements in the following media outlets: Frontdoors Magazine (Phoenix), Washington Times, Veterinary Practice News, Denver Business Journal, Townsend Letter for Doctors & Patients, Inc. Magazine, Dental Products Report, Woman’s World, Rocky Mountain News, Detroit News, Draft Horse Journal, Bridle and Bit, WB2 News Denver, KTVK-TV Phoenix (two segments), and KUSA 9News Gregg Moss gadget segment.
Circulation reach: 3,205,229
Ad Value Equivalent: $47,514.57
|
|
|
|
|
|
|
